Guides Collective Guides Collective Get matched with a guide
Answers for the psychedelic-curious

Can psychedelics help with depression? What the clinical trials show

In clinical trials, psilocybin has produced larger drops in depression scores than comparison doses — but the average difference in the biggest trials is modest, the evidence is still maturing, and no psychedelic is FDA-approved for depression. The one approved option in this space is esketamine (Spravato), a ketamine-derived drug for treatment-resistant depression.

By Troy Allen, Founder, Guides Collective Last updated: October 20, 2026

This page summarizes what published and company-reported trial results say, as of October 20, 2026. It describes research on study participants who were screened and monitored by clinical teams; it does not predict what would happen for any individual, and it is not medical advice. Decisions about depression treatment belong with a licensed clinician.

What the largest trials found

The most advanced program is Compass Pathways' synthetic psilocybin (COMP360) for treatment-resistant depression, studied in two Phase 3 trials. Both were company-sponsored, and as of the sources below the full datasets had not yet appeared in a peer-reviewed journal (HCPLive, Feb. 2026).

COMP005 (placebo-controlled; 258 U.S. participants; single 25 mg dose): at week 6, depression scores on the MADRS scale (0–60) were 3.6 points lower than placebo (95% CI −5.7 to −1.5; p<.001).
COMP006 (581 dosed participants; two doses three weeks apart; 25 mg vs a 1 mg comparison dose): at week 6, scores were 3.8 points lower in the 25 mg arm (95% CI −5.8 to −1.8; p<.001), and 39% of the 25 mg group had at least a 25% reduction in MADRS score.

Two things stand out. First, the differences are statistically significant but modest on a 60-point scale, and trial results describe group averages, not individual outcomes. Second, durability looks promising but is still being studied: Compass reported on July 7, 2026 that the 25 mg arm stayed separated from the 1 mg arm through week 26, with most adverse events occurring on dosing day. Serious adverse events over 26 weeks were 5.7% (25 mg) and 6.3% (1 mg). The most common adverse events were nausea, headache, anxiety, and visual hallucination. Suicidal ideation was reported in under 1% of participants across the studies, and one suicidal-behavior event occurred in the 1 mg arm of COMP006 (Compass Pathways, July 7, 2026; HCPLive, Feb. 2026).

What pooled analyses say — and the caveats

A living meta-analysis posted as a preprint (not yet peer reviewed) pooled randomized trials of psilocybin for depression: 12 trials with 711 participants in the database, and a pooled effect of Hedges' g = −0.91 (95% CI −1.35 to −0.48) in its primary model, with substantial heterogeneity (I² = 58%). The authors call the evidence "initial," and note that waitlist and crossover designs contributed much of the variation (medRxiv preprint, Aug. 2025).

Reviewers also flag recurring limits in this field: small samples, short follow-up, participants who were mostly white and middle-class, and functional unblinding — psychedelic effects are so noticeable that participants often know which arm they are in, which can inflate expectancy effects. Adverse events such as psychological distress and suicidality were inconsistently tracked in some early studies.

What isn't known yet

Long-term durability beyond about six months, how results compare with established treatments in head-to-head trials, which patients are most likely to be helped, and how outcomes translate outside tightly controlled trials. These are the questions the FDA review and ongoing studies, including a U.S. Department of Veterans Affairs psilocybin trial announced in August 2026, are meant to address.

Where access stands today

Psilocybin remains a Schedule I substance federally. Compass expects to complete its FDA submission in Q4 2026 and anticipates a launch in the first half of 2027, subject to FDA approval and DEA rescheduling — a company projection, not an FDA decision (Compass Pathways, July 7, 2026). Outside clinical trials, regulated adult programs exist only in Oregon and Colorado (see where psychedelics are legal in the US), and those programs are not medical treatment. For how psilocybin, ketamine, and MDMA differ on approval status, see psilocybin vs ketamine vs MDMA therapy.

If you are on an antidepressant or have a mood-disorder history: do not change any prescribed medication on your own. Read psilocybin and SSRIs and who should not take psychedelics, and talk to your prescriber first. If you are in crisis, call or text 988 (U.S.).

How a guide fits in

Guides are not clinicians and do not treat depression. If you are exploring this space, a vetted guide can help you think through preparation, questions to bring to your own clinician, and integration. See what a psychedelic guide actually does.

Talk it through with a vetted guide

Answer a few private questions, get connected with a guide curated for your circumstances, and start with a free consultation before you decide anything.

Start the free 5-minute questionnaire
Private · No commitment · No experience needed

Frequently asked questions

Is psilocybin FDA-approved for depression?+
No. Psilocybin is not FDA-approved for any condition and remains Schedule I. Compass Pathways has a rolling FDA submission underway for treatment-resistant depression and expects to complete it in Q4 2026; approval would also require DEA rescheduling. The only approved drug in this space is esketamine (Spravato), a ketamine-derived drug.
How big was the effect in the largest psilocybin depression trials?+
In Compass Pathways' two Phase 3 trials, depression scores (MADRS, 0–60) were about 3.6 to 3.8 points lower with the 25 mg dose than with the comparison at week 6, which was statistically significant. These are group averages from company-reported results and do not predict individual outcomes.
How long do the effects last?+
In COMP006, Compass reported that the 25 mg arm stayed separated from the 1 mg comparison arm through week 26 on average. Durability beyond roughly six months is not yet established, and results vary between individuals.
Can I stop my antidepressant to try psilocybin?+
Do not stop or taper a prescribed medication on your own. Antidepressants can blunt or complicate psychedelic effects, and stopping some of them abruptly carries its own risks. That decision belongs with your prescriber.
Can Guides Collective treat or diagnose depression?+
No. Guides Collective is an informational platform, not a medical provider, and guides are not clinicians. If you are struggling, please contact a licensed professional; in the U.S. you can call or text 988 any time.

Sources

Guides Collective is an informational platform that helps adults explore profiles of independent psychedelic guides. It is not a medical or mental-health provider and does not provide therapy, medical care, or psychedelic services.

All guides operate independently and are not employees, contractors, or agents of Guides Collective. Guides Collective does not verify guide-provided descriptions or credentials, does not recommend, endorse, or supervise any guide or service, and does not oversee or participate in any services guides offer.

Guides Collective does not provide or facilitate access to any substances. Each guide is solely responsible for their own services, communications, and compliance with local laws. Users are responsible for evaluating whether a guide's experience and approach are appropriate for their situation. No specific outcomes are promised or guaranteed.

Educational information on this page is provided for context only and does not constitute medical or legal advice, diagnosis, treatment, or therapeutic claims. Research findings describe study populations and do not predict individual outcomes. If you are in crisis, call or text 988 (U.S.).